8-K: Harvard Bioscience Secures $40M Debt Refinancing

Harvard Bioscience, Inc. announced a $40 million debt refinancing package with BroadOak Capital Partners, extending debt maturity and enhancing financial flexibility.

Summary

• Harvard Bioscience, Inc. (the Company) entered into a Loan and Security Agreement with BroadOak Income Fund, L.P. and other lenders for a new $40.0 million credit facility.
• The facility consists of a $10.0 million Term A Loan, a $22.5 million Term B Loan, and a $7.5 million Term C Loan, all maturing on December 17, 2029.
• The proceeds will be used to repay the Company's prior credit facility with Citizens Bank, N.A., cover transaction fees, and for working capital and general corporate purposes.
• Interest on the Term Loans will be the greater of (i) 12.80% (for the first two years, then 12.50%) or (ii) the Prime Rate plus 5.25%, payable monthly in cash, with an option for Term C Loan interest to be paid in kind.
• The Term C Loan is a senior secured convertible term loan, convertible into common stock at $1.00 per share, at the lenders' option from January 2, 2026, or automatically if the stock price exceeds $1.50 for 30 consecutive trading days after June 30, 2026, or upon a change of control.
• The Company issued warrants to the lenders to purchase 2,000,000 shares of common stock at an exercise price of $0.50 per share, with a seven-year term expiring December 17, 2032.
• Quarterly principal amortization payments on the Term A and Term B Loans will commence on December 31, 2027, at 5% of the principal amount.
• The Amortization Date and Maturity Date can be extended by one year if the Company achieves an Adjusted EBITDA milestone of at least $14.0 million (trailing twelve months) for two consecutive fiscal quarters ending on or before December 31, 2027.
• The Company's obligations are secured by substantially all of its assets and guaranteed by its domestic subsidiaries.
• Mr. William A. Snider, a partner at BroadOak, was appointed to the Company's Board of Directors (Class III) and the Compensation Committee, effective December 17, 2025, pursuant to BroadOak's nomination right.
• The Company will establish a Product, Operations and Scientific Advisory Board by March 31, 2026, including representatives from the Company and BroadOak.

Sentiment

Score: 6

Explanation: The successful refinancing provides much-needed stability and extends debt maturity, addressing a key financial objective. However, the high interest rates, significant fees, and potential for shareholder dilution from the convertible loan and warrants represent substantial costs. The strategic partnership with BroadOak and the establishment of an advisory board offer potential long-term benefits.

Positives

• Successfully refinanced existing debt, eliminating near-term maturity risk and strengthening the balance sheet.
• Extended debt maturity to December 17, 2029, with a potential one-year extension to December 17, 2030, if certain EBITDA milestones are met.
• Enhanced financial flexibility through the new credit facility and proceeds for working capital and general corporate purposes.
• Secured a strategic partner in BroadOak Capital Partners, a life-sciences-focused investment firm, which also gains board representation and advisory board participation.
• The new board member, Mr. William A. Snider, brings over 30 years of institutional investment experience and expertise in life science tools.

Negatives

• The Term Loans bear a high interest rate, starting at 12.80% per annum, which will increase the Company's cost of capital.
• Significant prepayment premiums (3.00% in Year 1, 2.00% in Year 2, 1.00% in Year 3) and a 10.00% exit fee (with potential reduction) apply to repayments, making early debt reduction costly.
• The issuance of warrants for 2,000,000 shares at $0.50 per share and the convertible Term C Loan at $1.00 per share pose a risk of significant shareholder dilution.
• The Company is subject to financial covenants, including a minimum liquidity of $3.0 million and minimum Adjusted EBITDA targets ($6.0 million through Q3 2027, then $8.0 million thereafter, trailing twelve months), which could restrict operations if not met.
• The Term C Loan may not be prepaid prior to maturity without lender consent, except in specific circumstances, limiting the Company's flexibility to refinance this portion.

Risks

• Failure to achieve the Adjusted EBITDA milestone of $14.0 million by December 31, 2027, would prevent the one-year extension of the Amortization Date and Maturity Date.
• Inability to comply with the minimum liquidity covenant of $3.0 million or the Adjusted EBITDA covenants could trigger an Event of Default.
• The potential for significant shareholder dilution from the exercise of 2,000,000 warrants and the conversion of the $7.5 million Term C Loan into common stock.
• The Company's common stock could be delisted from NASDAQ if it fails to comply with continued listing standards, although failure to maintain the minimum bid price alone is not an Event of Default unless it leads to actual delisting.
• The Company must file a registration statement for the resale of shares issued upon conversion of the Term C Loan and exercise of the Warrants, and failure to get it effective within specified timelines could have adverse implications.

Future Outlook

The Company anticipates that this financing package will provide the stability and flexibility needed to execute its strategic priorities and drive long-term value. Management believes the Company's preclinical and translational research platforms are well positioned regarding new approach methodologies being implemented by the FDA and other regulators.

Management Comments

• John Duke, CEO: 'This financing package meets our objectives and is an important milestone for Harvard Bioscience that provides us with the stability and flexibility we need moving forward.'
• John Duke, CEO: 'By successfully refinancing our near-term debt obligations and enhancing our liquidity profile we are positioned well to execute our strategic priorities and drive long-term value.'
• Bill Snider, Partner at BroadOak: 'I have known Harvard Bioscience for many years and believe that with this financing and the recent organizational improvements, it is stronger than ever.'
• Bill Snider, Partner at BroadOak: 'In addition, the Company's preclinical and translational research platforms are well positioned regarding the new approach methodologies roadmaps being implemented by FDA and other regulators. I am excited to be joining the board and look forward to partnering with and supporting the team as they establish a leadership position in these emerging initiatives.'
• Katherine Eade, Lead Independent Director: 'Bills invaluable experience and expertise and his confidence in the Company strengthen us and our resolve to drive significant value creation for Harvard Biosciences shareholders.'

Industry Context

This debt refinancing positions Harvard Bioscience within the life sciences research tools sector, aligning with broader industry trends towards preclinical and translational research. The involvement of BroadOak Capital Partners, a firm specializing in life sciences, underscores the strategic importance of this sector. The mention of FDA's new approach methodologies suggests the Company is aiming to capitalize on evolving regulatory landscapes in drug and therapy development.

Comparison to Industry Standards

• The interest rate of 12.80% (initially) is relatively high, suggesting a higher perceived risk profile for Harvard Bioscience compared to more established, lower-risk companies in the life sciences tools sector that might secure financing at lower rates.
• The inclusion of warrants (2,000,000 shares at $0.50) and a convertible loan ($7.5 million at $1.00 conversion price) is common in growth capital or distressed financing scenarios, providing lenders with equity upside potential in exchange for providing capital to companies that may have limited access to traditional debt markets.
• The right for BroadOak to nominate a board member and participate in an advisory board is a typical feature in such financing arrangements, allowing the lender to exert influence and provide strategic guidance, particularly in situations where the company is seeking operational improvements or strategic shifts.
• The financial covenants, including minimum liquidity and Adjusted EBITDA targets, are standard for debt agreements, but the specific thresholds will need to be assessed against the Company's historical performance and industry peers to determine their stringency.
• The prepayment premiums and exit fees are aggressive, indicating a strong incentive for the Company to maintain the debt for its full term and compensate lenders for foregone interest income if repaid early, which is not uncommon for non-bank lenders in this space.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from the warrants and convertible Term C Loan, but benefit from reduced near-term refinancing risk and extended debt maturity. The high cost of debt may impact future earnings.
• Lenders (BroadOak Capital Partners): Gain a secured position, high interest income, potential equity upside through warrants and convertible debt, and direct influence via a board seat and advisory board participation.
• Employees: Benefit from increased financial stability and a clearer path for the company's operations.
• Customers and Suppliers: Likely to see continued operational stability and potentially improved long-term business relationships due to the strengthened capital structure.
• Creditors: The new senior secured debt facility provides a clear repayment structure, but the high interest rates and fees reflect the perceived risk of the Company.

Next Steps

• The Company must prepare and file a registration statement with the SEC within 45 days of the Closing Date, covering the resale of all shares issued and issuable upon conversion of the Term C Loan and exercise of the Warrants.
• The Company will use reasonable best efforts to cause the registration statement to be declared effective by the SEC within 75 days (if reviewed) or 5 business days (if not reviewed) of filing.
• The Company will establish a Product, Operations and Scientific Advisory Board before March 31, 2026, to advise on commercial, product, manufacturing, and performance opportunities.

Key Dates

Recommendation

The refinancing addresses immediate liquidity and maturity concerns, providing a necessary lifeline and stability. However, the high cost of capital (interest rates, fees, and potential dilution from warrants and convertible debt) will weigh on future profitability and shareholder value. The strategic partnership with BroadOak and the new advisory board offer potential operational improvements, but the financial terms suggest underlying challenges. Investors should hold to monitor the company's ability to execute its strategic priorities, improve Adjusted EBITDA, and manage the dilution risk, as the current terms reflect a higher risk profile.

Keywords

Harvard Bioscience, HBIO, Debt Refinancing, Term Loan, Convertible Debt, Warrants, BroadOak Capital Partners, SEC Filing, Corporate Finance, Life Sciences, NASDAQ, EBITDA Covenant, Liquidity